Nuvation Bio shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $1.40 to $10.
Portfolio Pulse from Benzinga Newsdesk
Nuvation Bio's stock (NUVB) experienced a significant increase after Jefferies upgraded its rating from Hold to Buy and raised the price target from $1.40 to $10.
March 27, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nuvation Bio's stock received a major upgrade from Jefferies, moving from Hold to Buy, with a significant increase in the price target from $1.40 to $10.
The upgrade by Jefferies from Hold to Buy, accompanied by a substantial increase in the price target for Nuvation Bio, suggests a strong bullish outlook on the stock by the firm. This is likely to generate positive investor sentiment and could lead to a short-term increase in the stock price, as the market adjusts to the new valuation implied by the higher price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100